Relief Therapeutics and FirstString Research Collaborate to Develop Atexakin Alfa

Biotech Relief Therapeutics Holding (SIX: RLF) today declares a new collaboration agreement between its subsidiary, Relief Therapeutics, and FirstString Research to develop atexakin alfa in the United States.

According to the press release:

“FirstString will seek US government financial support, develop relevant collaborations, and provide resources towards the Food and Drug Administration (FDA) requirements on the constitution of an Investigational New Drug (IND) application dossier for atexakin alfa in Diabetic Neuropathy. This collaboration is in line with the intention of both companies, operating in the area of diabetic complications, to develop a stronger research and commercial relationship.”

Gaël Hédou, CEO of Relief Therapeutics, said the following:

“We are delighted to take a concrete step toward an effective collaboration with FirstString. Not only will it allow us to progress atexakin alfa toward its clinical development in the US, but it anticipates our future company growth that is planned with FirstString.”

Read the full press release here.